25 results about "Immunooncology" patented technology

Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.

Described here are methods to utilize genomic and epigenomic detection platforms to provide quantitative metrics, including those representative of molecular phenotypes, in a variety of iimmuno-oncology applications, including those related to the characterization of patient responsiveness, treatment efficacy, adverse events among otheres. In various embodiments, described herein is an example of generating prognostic and t outcomes of a cfDNA-derived promoter methylation score in predicting ICI benefit.

Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.

The present invention relates to the field of biotechnology and immunooncology. The invention discloses a bispecific antibody. The bispecific antibody comprises an antibody, an antibody fragment or a single-chain variable fragment for recognizing NGcGM3 ganglioside on tumor cells and an antibody, an antibody fragment or a single-chain variable fragment for recognizing a CD3 antigen on human immune effector cells. These bispecific antibodies are characterized in that they are capable of mediating selective cytotoxicity against NGcGM3-positive tumor cells, rather than normal cells capable of expressing the gangliosides, and allow recruitment of not only T lymphocytes but also NKT. The bispecific antibodies of the invention, as well as the nucleic acids encoding them, are useful for the treatment of lymphoproliferative diseases and solid tumors expressing NGcGM3.

The field of the invention is in vitro assays for the production of in vitro organ culture systems and the use of such in vitro organ culture systems for screening assays in drug screening, patient selection and personalized medical context. More specifically, the present invention relates to an in vitro method of establishing a tumor organoid from a cancer tissue sample obtained from a subject, an in vitro method of providing immune cells activated by an autologous tumor organoid, a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject, and a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject. The invention relates to an in vitro organ culture system, and to an in vitro organ culture system produced thereby, to a method for determining the reactivity of a tumor to at least one immunooncology drug therapy using said in vitro organ culture system, and to a kit for preparing an in vitro organ culture system that mimics the interaction of a tumor with the immune system of a subject, as disclosed herein.

It has been conventionally known that a Toxicodendron vernicifluum extract is effective in treating arthritis and the like by suppressing immunity. However, in the present invention, it has been experimentally demonstrated that treatment of cytokine-induced killer cells with a Toxicodendron vernicifluum extract actually increases the immune sensitivity of immune cells, resulting in improved cancer cell killing ability. Therefore, an immune-anticancer composition comprising a Toxicodendron vernicifluum extract and cytokine-induced killer cells as active ingredients, of the present invention, can effectively treat lung cancer or breast cancer by means of improved cancer cell killing ability, and, when prepared, an anticancer immune cell therapeutic preparation comprising same can be administered to patients with lung cancer and patients with breast cancer so as to effectively treat lung cancer and breast cancer.

Disclosed herein are extracellular vesicles comprising an immunomodulatory component. Methods of producing the extracellular vesicles and methods of using the extracellular vesicles to treat cancer, GvHD, and autoimmune diseases are also provided.

Disclosed herein are extracellular vesicles comprising immunomodulatory components. Also provided are methods of producing extracellular vesicles and methods of using extracellular vesicles to treat cancer, GvHD, and autoimmune diseases.

Provided herein are methods, devices, and kits for identifying glycosylated polypeptide biomarkers and signatures for progression of a disease or a condition, such as cancer or NASH, or and response of the disease or condition to a treatment. Also provided herein are: i) methods of generating and analyzing glycosylated polypeptide biomarkers, ii) methods of validating a model using glycosylated polypeptides for predicting the disease or condition or for making treatment recommendation, iii) systems and methods for implementing QC of a cohort of samples by analyzing peptide structure data for each sample using a machine learning model to generate a predicted age and / or sex associated for each sample. The quality control issue may include an error of mislabeled samples or an error from sample preparation, or a systemic measurement or an instrument error.

The ordered peptide nanofiber hydrogel, preparation method and application of the application relate to the technical field of biomaterials and immunology and tumor, and the hydrogel is formed by regulating the self-assembly process of Fmoc-FFE short peptides in a specific buffer solution, and the inside presents a highly ordered arrangement of nanofibers.The ordered peptide nanofiber hydrogel of the application not only has excellent biocompatibility and adjustable mechanical properties, but also can highly simulate the ordered remodeling of extracellular matrix collagen fibers in the development process of solid tumors in vitro.The ordered hydrogel can significantly promote the proliferation, invasion and directional migration of breast tumor cells; the ordered microstructure constructs a physical and mechanical barrier in the tumor immune microenvironment, significantly inhibits the infiltration and activation of T cells, and induces T cell exhaustion.The application provides an ideal in vitro three-dimensional (3D) model for in-depth study of the complex interaction between the ordered ECM regulated tumor promoting mechanism and the inhibition of immune cells.

The present invention relates to compounds of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, (Ia) wherein: ring A is a 5- or 6-membered monocyclic aromatic or heteroaromatic ring, or a 9- or 10-membered bicyclic aromatic or heteroaromatic ring, each of which is optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, alkoxy, NR11R11′, OH, SO2-alkyl, CO2-alkyl, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, and wherein said aryl and heteroaryl substituents are in turn optionally substituted with one or more substituents each independently selected from F, Cl, Br, I, CN, alkoxy, NR11R11′, OH, alkyl, haloalkyl, and aralkyl; ring B is a monocyclic or bicyclic heteroaromatic group containing at least one nitrogen atom, which is optionally substituted by one or more substituents selected from halo, CN, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, CO2-alkyl, O-aryl, NR11R11′, CONR16R17 and SO2NR16R17; Y and Z are each independently CR10R10′, wherein R10 and R10′ are each independently selected from H, F, alkyl, and haloalkyl; and R11 and R11′ are each independently selected from H, alkyl, haloalkyl, COR12, and SO2R13, wherein R12 and R13 are each independently alkyl; R16 and R17 are each independently selected from H and alkyl; P wherein the compound is other than 6-fluoro-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxamide. Further aspects of the invention relate to such compounds for use in the field of immuno-oncology, immunology, and related applications.

One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5- or 6-membered aromatic or heteroaromatic ring, wherein said aromatic or heteroaromatic ring is optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, alkoxy, NR11R11',OH, alkyl, haloalkyl, aralkyl, aryl and heteroaryl, and wherein said aryl and heteroaryl substituents are in turn optionally substituted with one or more substituents, each independently selected from F, Cl, Br, I, CN, alkoxy, NR11R11' OH, alkyl, haloalkyl and aralkyl; And is selected from C=N-OH and CR10R10' wherein R10 and R10' are selected independently from H, F, alkyl and haloalkyl; R1, R4 and R5 are selected independently from H, F, Cl, Br and I; R2 and R3 are selected independently from H, F, Cl, Br, I, CN, methoxy and haloalkyl;and R11 and R11' are independently selected from H, alkyl, haloalkyl, COR12 and SO2R13, wherein R12 and R13 are both alkyl; for use as a medicament. Other aspects of the invention relate to compounds of formula (I) for use in the field of immuno-oncology, immunology and related applications, and to compounds of formula (I) per se.

It has been known that, conventionally, a Toxicodendron vernicifluum extract has an effect of treating arthritis and the like by suppressing immunity. However, in the present invention, it has been experimentally demonstrated that treatment of cytokine-induced killer cells with a Toxicodendron vernicifluum extract actually increases the immune sensitivity of immune cells, resulting in improved cancer cell killing ability. Therefore, an immune-anticancer composition comprising a Toxicodendron vernicifluum extract and cytokine-induced killer cells as active ingredients, of the present invention, can effectively treat lung cancer or breast cancer with improved cancer cell killing ability, and, when an anticancer immune cell therapeutic preparation comprising same is prepared, the preparation is administered to patients with lung cancer and breast cancer so as to effectively treat lung cancer and breast cancer.

Adenosine receptor (e.g., A2A and / or A1 receptor) antagonist compounds and compositions including the adenosine receptor antagonist compounds are disclosed. Methods of using the compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and / or A1 receptor in a biological system are also disclosed. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease.

One aspect of the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as a medicament, wherein: ring A is a 5- or 6-membered aromatic ring or heteroaromatic ring, wherein the aromatic ring or heteroaromatic ring is optionally selected from F, Cl, Br, I, CN, alkoxy, NR 11 R 11 One or more substituents of ', OH, alkyl, haloalkyl, aralkyl, aryl, and heteroaryl, wherein said aryl and heteroaryl substituents are optionally each independently selected from F, Cl, Br, I, CN, alkoxy, NR 11 R 11 One or more substituents selected from ', OH, alkyl, haloalkyl, and aralkyl; Y is selected from C=N-OH and CR 10 R 10' , where R 10 and R 10' Each is independently selected from H, F, alkyl, and haloalkyl; R1, R4, and R5 are each independently selected from H, F, Cl, Br, and I; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, methoxy, and haloalkyl; and R 11 and R 11 Each is independently selected from H, alkyl, haloalkyl, COR 12 and SO2R 13 , where R 12 and R 13 All are alkyl groups. The invention also relates to the use of compounds of formula (I) in immuno-oncology, immunology, and related applications, as well as to compounds of formula (I) themselves.

The invention relates to genome editing systems, reagents and methods for immunooncology.

Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.

The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.

The method includes compressing numbers of reads data for targeted genes of a gene expression assay performed on a test sample. The targeted genes are organized into categories. Each category represents a functional context associated with the targeted genes in that category. The numbers of reads corresponding to targeted genes each category is compressed to form a compressed value for the category. The compressed value is compared to a baseline value for the category to determine an enrichment or a loss of a signature corresponding to the functional context of the category. The method may include analyzing information from multiple assays performed on the test sample, assigning a score value to each assay result and predicting a response to immune-oncology treatment based on the assigned scores.

One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (Formula (I)) wherein: ring B is: a monocyclic aromatic group; or a monocyclic or bicyclic heteroaromatic group, each of which is optionally substituted by one or more substituents selected from halo, CN, OH, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxycycloalkyl, O-cycloalkyl, alkoxy, haloalkoxy, heterocycloalkyl, O-heterocycloalkyl, aryl, heteroaryl, O-aryl, NHCO-alkenyl and CO2-alkyl, wherein said aryl, heteroaryl and O-aryl groups are each optionally further substituted by one or more groups independently selected from halo, alkyl, haloalkoxy and alkoxy; a is a single bond, Z is NR7, b is a double bond and Y is CR8; or a is double bond, Z is N, b is a single bond and Y is CR8R9; X is selected from O and S; R6 and R7 are each independently selected from H, alkyl, cycloalkyl and hydroxyalkyl. R8 and R9 are each independently selected from H, F, alkyl, and haloalkyl; and Ra and Rb are each independently selected from H and alkyl. Further aspects of the invention relate to compounds of formula (I) for use as a medicament, particularly in the field of immuno-oncology, immunology, and related applications.

The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (III), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof: The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.

This invention relates to compounds of formula (Ia), or pharmaceutically acceptable salts or hydrates thereof, wherein: groups X-Y are -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and tetrazolyl; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 Optionally substituted heteroaryl and alkyl groups; R8 is selected from H, alkyl, haloalkyl, and halogen; R9 is H, C1-C3 alkyl, or halogen; R 10 and R 11 Together with the nitrogen atoms to which they are attached, they form an azircyclic heptyl group, wherein (a) the azircyclic heptyl group is substituted with one or more substituents, or (b) one or two carbons of the azircyclic heptyl group are substituted with a group selected from O, NH, S and CO, and the azircyclic heptyl group is optionally further substituted; or R 10 and R 11 Together with the nitrogen atoms to which they are attached, they form an azircyclic butyl, pyrrolidinyl, or piperidinyl group, wherein (a) the azircyclic butyl, pyrrolidinyl, or piperidinyl group is substituted by one or more substituents, or (b) one or two carbon atoms of the azircyclic butyl, pyrrolidinyl, or piperidinyl group are substituted by a group selected from NH, S, and CO; or R 10 and R 11 Together with the nitrogen atoms to which they are attached, they form 8-, 9-, or 10-membered bicyclic heterocyclic alkyl groups, wherein one or two carbons of the bicyclic heterocyclic alkyl ring are optionally replaced by groups selected from O, NH, S, and CO, and the bicyclic heterocyclic alkyl group is optionally substituted; or R 10 and R 11 Together with the nitrogen atoms to which they are attached, they form 6- to 12-membered bicyclic groups containing spirocyclic carbon atoms, wherein one or both carbons of the bicyclic group are optionally replaced by a group selected from O, NH, S, and CO, and the bicyclic group is optionally substituted or optionally fused with a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 Each compound is independently H or alkyl. Other aspects of the invention relate to the use of such compounds in the field of immuno-oncology and related applications.

Conventionally, a Toxicodendron vernicifluum extract has been known to exert therapeutic effects on diseases such as arthritis by suppressing immune responses. However, the present disclosure experimentally demonstrates that treatment of cytokine-induced killer cells with a Toxicodendron vernicifluum extract actually increases the immune sensitivity of immune cells, resulting in improved cancer cell-killing ability. Accordingly, the immuno-oncologic composition comprising Toxicodendron vernicifluum extract and cytokine-induced killer cells as active ingredients according to the present invention provides enhanced cancer cell cytotoxicity for effective treating lung cancer or breast cancer. An anticancer immunotherapy product, when formulated with the composition, can be administered to patients with lung or breast cancer so as to effectively treat lung cancer and breast cancer.